Cymbalta for chronic pain
Eli Lilly submits supplemental new drug application in the second quarter for Cymbalta (duloxetine) in the management of chronic pain, the firm announces May 29. With an expected 10-month review, the drug's likely PDUFA timeframe would be February to March 2009. The drug was approved for acute and maintenance treatment of major depressive disorder Nov. 30; it is also approved for acute treatment of generalized anxiety disorder and management of diabetic peripheral neuropathic pain, all in adults 18 and older. An sNDA for use of the drug in fibromylagia is under FDA review, with an expected PDUFA data in June
You may also be interested in...
Industry-funded survey by Charles River Associates explores diverse perceptions about pricing for high-cost cell treatments – including curative cell and gene therapy – among various stakeholder groups.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
A study of drug approvals over more than three decades shows antimicrobials, including antibacterials, had consistently shorter development and review times than other types of products. While antibacterials were less likely to participate in special US FDA programs designed to help along review, experts said reimbursement reform, not new regulatory flexibility, is needed to help address the crisis of drug-resistant infections.